Mirati Therapeutics, Inc. (NASDAQ:MRTX) was the recipient of unusually large options trading on Friday. Investors purchased 4,659 call options on the stock. This is an increase of approximately 1,101% compared to the typical volume of 388 call options.
MRTX stock traded down $3.23 during mid-day trading on Friday, hitting $165.79. The company had a trading volume of 11,883 shares, compared to its average volume of 467,613. The company has a market capitalization of $8.56 billion, a price-to-earnings ratio of -16.80 and a beta of 1.37. Mirati Therapeutics has a 12-month low of $131.46 and a 12-month high of $249.42. The company has a 50-day moving average price of $158.41 and a 200 day moving average price of $163.74.
Mirati Therapeutics (NASDAQ:MRTX) last released its quarterly earnings results on Thursday, August 5th. The biotechnology company reported ($3.23) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.40) by ($0.83). On average, research analysts forecast that Mirati Therapeutics will post -11.76 earnings per share for the current fiscal year.
Several research analysts have recently issued reports on MRTX shares. Morgan Stanley assumed coverage on Mirati Therapeutics in a research report on Thursday, August 26th. They issued an “equal weight” rating and a $160.00 target price for the company. JPMorgan Chase & Co. decreased their price target on shares of Mirati Therapeutics from $205.00 to $203.00 and set an “overweight” rating for the company in a research note on Tuesday, September 7th. Citigroup upgraded shares of Mirati Therapeutics from a “neutral” rating to a “buy” rating in a research note on Friday, June 4th. upgraded shares of Mirati Therapeutics from a “neutral” rating to a “buy” rating in a research note on Friday, June 4th. Finally, Oppenheimer reissued a “market perform” rating and issued a $160.00 target price (down previously from $245.00) on shares of Mirati Therapeutics in a report on Monday, May 24th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $210.25.
Mirati Therapeutics Company Profile
Mirati Therapeutics, Inc operates as a clinical-stage oncology company, which engages in the development of novel therapeutics. The firm’s products targets the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995 and is headquartered in San Diego, CA.
Further Reading: What are popular green investing opportunities?
Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.